About Medirize Pharmaceuticals Private Limited
Data last updated:
Medirize Pharmaceuticals Private Limited was a private limited company based in Hyderabad, Telangana, India. The company has been struck off by the Registrar of Companies, typically due to non-filing of annual returns or failure to commence business. It is no longer operational and cannot enter into any legal contracts or agreements. It operated in the wholesale trading and distribution segment of the trading and commerce sector. It was incorporated on 18 December 2015.
The company was registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24233TG2015PTC102330. Its GSTIN is 36AAKCM0726E1ZO (Telangana).
The company had an authorised share capital of ₹10 Lakh and a paid-up capital of ₹10 Lakh. It was led by directors Krishna Priyanka Pappula and Radhika Chintalapudi.
Its last annual general meeting (AGM) was held on 29 September 2018, and its latest financial statements are for the year ended 31 March 2018. The registered office was at Flat No. 101 R S Plaza Street No.1 Karthikeya Nagar Nacharam, Hyderabad, Telangana, India – 500076.
As per the financials filed for FY 2018, the company reported a revenue of ₹44.27 Lakh, a growth of 8% compared to the previous year. For the same year it recorded a net profit of ₹13,554 (net margin 0.3%) and EBITDA of ₹18,324 (EBITDA margin 0.4%).
The last known website on record is medirize.com.
Company details
Contact details
Medirize Pharmaceuticals Private Limited's registered office is in Hyderabad, Telangana. Its website is medirize.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressFlat No. 101 R S Plaza Street No.1 Karthikeya Nagar Nacharam, Hyderabad, Telangana, India – 500076
- IndustryTrading, Wholesale, Other Wholesale
To see the full contact details of Medirize Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Medirize Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Medirize Pharmaceuticals Private Limited, buy the company report.
Financials of Medirize Pharmaceuticals Private Limited
FY 2018 filings availableMedirize Pharmaceuticals Private Limited reported revenue of ₹44.27 Lakh (up 8% YoY) for FY 2018.
Compounded Annual Growth Rate (CAGR)
Revenue rose 8% in the latest year. EBITDA rose 129% in the latest year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2017-18 | FY 2016-17 | FY 2015-16 |
|---|---|---|---|
| Profit and Loss Statement | |||
| Revenue from Operations | ₹44.27 Lakh | ||
| Other Income | |||
| Total Revenue | |||
| Cost of Materials Consumed | |||
| Employee Benefit Expense | |||
| Finance Costs | |||
| Depreciation and Amortisation | |||
| Other Expenses | |||
| Total Expenses | |||
| EBITDA | ₹18,324 | ||
| Profit Before Tax | |||
| Tax Expense | |||
| Net Profit (PAT) | ₹13,554 | ||
| Balance Sheet | |||
| Share Capital | |||
| Reserves and Surplus | |||
| Net Worth (Total Equity) | |||
| Long-term Borrowings | |||
| Short-term Borrowings | |||
| Trade Payables | |||
| Total Liabilities | |||
| Fixed Assets | |||
| Investments | |||
| Inventories | |||
| Trade Receivables | |||
| Cash and Bank Balance | |||
| Total Assets | |||
Financial Ratios
| Metrics | FY 2017-18 | FY 2016-17 | FY 2015-16 |
|---|---|---|---|
| Profitability | |||
| EBITDA Margin | 0.4% | ||
| Net Profit Margin | 0.3% | ||
| Return on Equity (ROE) | |||
| Return on Capital Employed (ROCE) | |||
| Return on Assets (ROA) | |||
| Liquidity and Debt | |||
| Current Ratio | |||
| Quick Ratio | |||
| Debt-to-Equity Ratio | |||
| Interest Coverage Ratio | |||
| Efficiency and Growth | |||
| Asset Turnover | |||
| Receivable Days | |||
| Payable Days | |||
| Inventory Days | |||
| Revenue Growth | |||
| Net Profit Growth | |||
To see the full financial statements and ratios of Medirize Pharmaceuticals Private Limited, buy the company report.
Board of directors of Medirize Pharmaceuticals Private Limited
Medirize Pharmaceuticals has 2 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Krishna Priyanka Pappula Also directs: Medirize Aquatech Private Limited | Director | 18 Dec 2015 | 10 Years 10 Months | As last reported |
| Radhika Chintalapudi Also directs: Medirize Aquatech Private Limited | Director | 18 Dec 2015 | 10 Years 10 Months | As last reported |
Peer comparison
Medirize Pharmaceuticals Private Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Arka Biologics Private Limited | ₹44.33 Lakh (FY 2016) | -71.0% | Ahmedabad, Gujarat, India | |||
| Monarda Pharmaceuticals Private Limited | ₹44.33 Lakh (FY 2024) | 151.0% | Thakurpur, Uttarakhand, India | |||
| Siba Life Sciences Limited | ₹44.3 Lakh (FY 2024) | -44.0% | New Delhi, Delhi, India | |||
| Medirize Pharmaceuticals Private Limitedthis company | ₹44.27 Lakh (FY 2018) | ₹13,554 | 0.3% | 8.0% | Hyderabad, Telangana, India | |
| Moxy Laboratories Private Limited | ₹44.24 Lakh (FY 2024) | -18.0% | Vadodara, Gujarat, India | |||
| Ultra Chiron Healthcare Private Limited | ₹44.19 Lakh (FY 2025) | -31.0% | Punjab, India |
To see the full peer comparison of Medirize Pharmaceuticals Private Limited, buy the company report.
Auditor
Medirize Pharmaceuticals Private Limited is audited by RAO & BABU ASSOCIATES for the financial year 2018.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| RAO & BABU ASSOCIATES | FY 2018 | 005977S |
Shareholding
The shareholding of Medirize Pharmaceuticals Private Limited is on record for 3 financial years, the latest being FY 2018, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|
| Promoters | |||
| Domestic institutional investors (DII) | |||
| Foreign institutional investors (FII) | |||
| Public | |||
| Others |
To see the full shareholding pattern of Medirize Pharmaceuticals Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Medirize Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Medirize Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Medirize Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AAKCM0726E1ZO | Telangana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Medirize Pharmaceuticals Private Limited, buy the company report.
Recent activity
Medirize Pharmaceuticals Private Limited has 3 board changes on record since 2015: 2 appointments and 1 cessation. The latest: Seetha Rama Raju Pappala ceased to be Director on 21 Jan 2020.
Frequently asked questions
Medirize Pharmaceuticals has a status of "Struck Off" as per MCA records. This means the company has been officially removed from the Register of Companies, typically due to non-filing of annual returns or failure to commence business within one year of incorporation. A struck-off company cannot enter into any legal contracts or agreements, and any dealings with such an entity carry significant legal and financial risk.
Medirize Pharmaceuticals was a private limited company based in Hyderabad, Telangana, India. The company worked in wholesale, within the trading industry. It was incorporated on 18 December 2015 and is registered under CIN U24233TG2015PTC102330. The company has been struck off by the Registrar of Companies and is no longer operational.
Medirize Pharmaceuticals had 2 directors:
- Krishna Priyanka Pappula - Director
- Radhika Chintalapudi - Director
The CIN (Corporate Identification Number) of Medirize Pharmaceuticals is U24233TG2015PTC102330. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
The registered office of Medirize Pharmaceuticals is at Flat No. 101 R S Plaza Street No.1 Karthikeya Nagar Nacharam, Hyderabad, Telangana, India – 500076.
Medirize Pharmaceuticals was incorporated on 18 December 2015. It is registered with the Registrar of Companies, Hyderabad.
Medirize Pharmaceuticals can be reached through the website medirize.com. Its registered office is in Hyderabad, Telangana, India.
The latest financial statements of Medirize Pharmaceuticals on record with the MCA are for the year ended 31 March 2018. Its last annual general meeting was held on 29 September 2018. Year-wise statements from FY 2016 are in the company report.
The GSTIN of Medirize Pharmaceuticals is 36AAKCM0726E1ZO, registered in Telangana.
Medirize Pharmaceuticals operated in the trading industry, in the wholesale segment. It worked in this industry before it was struck off.
The peers of Medirize Pharmaceuticals by revenue are Arka Biologics Private Limited, Monarda Pharmaceuticals Private Limited, Siba Life Sciences Limited, Moxy Laboratories Private Limited, Ultra Chiron Healthcare Private Limited, all in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals), with the same principal business activity (wholesale trading).